Document Detail

Cancer-Related Lymphedema Risk Factors, Diagnosis, Treatment, and Impact: A Review.
MedLine Citation:
PMID:  23008299     Owner:  NLM     Status:  Publisher    
PURPOSECancer-related lymphedema (LE) is an incurable condition associated with lymph-involved cancer treatments and is an increasing health, quality of life (QOL), and cost burden on a growing cancer survivor population. This review examines the evidence for causes, risk, prevention, diagnosis, treatment, and impact of this largely unexamined survivorship concern. METHODSPubMed and Medline were searched for cancer-related LE literature published since 1990 in English. The resulting references (N = 726) were evaluated for strength of design, methods, sample size, and recent publication and sorted into categories (ie, causes/prevention, diagnosis, treatment, and QOL). Sixty studies were included.ResultsExercise and physical activity and sentinel lymph node biopsy reduce risk, and overweight and obesity increase risk. Evidence that physiotherapy reduces risk and that lymph node status and number of malignant nodes increase risk is less strong. Perometry and bioimpedence emerged as attractive diagnostic technologies, replacing the use of water displacement in clinical practice. Swelling can also be assessed by measuring arm circumference and relying on self-report. Symptoms can be managed, not cured, with complex physical therapy, low-level laser therapy, pharmacotherapy, and surgery. Sequelae of LE negatively affect physical and mental QOL and range in severity. However, the majority of reviewed studies involved patients with breast cancer; therefore, results may not be applicable to all cancers. CONCLUSIONResearch into causes, prevention, and effect on QOL of LE and information on LE in cancers other than breast is needed. Consensus on definitions and measurement, increased patient and provider awareness of signs and symptoms, and proper and prompt treatment/access, including psychosocial support, are needed to better understand, prevent, and treat LE.
Electra D Paskett; Julie A Dean; Jill M Oliveri; J Phil Harrop
Related Documents :
24489939 - Association of matrix metalloproteinase-3 -1171(5a>6a) polymorphism with cancer risk: a...
23957659 - Childhood adversity as a risk for cancer: findings from the 1958 british birth cohort s...
23381039 - Comparative effectiveness of alternative prostate-specific antigen--based prostate canc...
24503029 - Cancer incidence and incidence rates in japan in 2008: a study of 25 population-based c...
2409039 - Who guidelines for the use of analgesics in cancer pain.
24923229 - Risk of subsequent cancers in renal cell carcinoma survivors with a family history.
23364839 - In vivo molecular imaging of gastric cancer by targeting mg7 antigen with confocal lase...
25469259 - Induction of caspase cascade pathway by kaempferol-3-o-rhamnoside in lncap prostate can...
25054819 - Interview: molecular neuro-oncology: a forward-looking perspective.
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-9-24
Journal Detail:
Title:  Journal of clinical oncology : official journal of the American Society of Clinical Oncology     Volume:  -     ISSN:  1527-7755     ISO Abbreviation:  J. Clin. Oncol.     Publication Date:  2012 Sep 
Date Detail:
Created Date:  2012-9-25     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8309333     Medline TA:  J Clin Oncol     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
All authors: The Ohio State University, Columbus, OH.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Late cardiac effects of cancer treatment.
Next Document:  Long-Term Results of the Randomized Phase III Trial EORTC 18991 of Adjuvant Therapy With Pegylated I...